Dismiss Notice
You are browsing this site as a guest. It takes 2 minutes to CREATE AN ACCOUNT and less than 1 minute to LOGIN

Africa malaria drugs 'low-grade'

Discussion in 'Habari na Hoja mchanganyiko' started by BAK, Feb 9, 2010.

  1. BAK

    BAK JF-Expert Member

    #1
    Feb 9, 2010
    Joined: Feb 11, 2007
    Messages: 49,978
    Likes Received: 9,623
    Trophy Points: 280
    Africa malaria drugs 'low-grade'

    BBC News Online


    [​IMG]
    The experts say their research threw up a disturbing trend

    Africans suffering from malaria may be getting sub-standard treatment, a study by US-based experts has suggested. Researchers from the Pharmacopeia group found that between 26% and 44% of anti-malaria drugs in Uganda, Senegal and Madagascar were of poor quality.

    The group, conducting the study for the World Health Organization, said low-grade drugs were being used in both public and private health practices.
    Some 90% of malaria deaths in the world occur in Africa.
    The experts subjected 200 samples of anti-malaria drugs to quality-control testing in a US laboratory.

    They found 44% of the drugs from Senegal failed the testing, followed by 30% from Madagascar and 26% from Uganda.
    Patrick Lukulay, director of the US government-funded Pharmacopeia programme, said it was a "disturbing trend".

    "It is worrisome that almost all of the poor-quality data that was obtained was a result of inadequate amounts of active [ingredients] or the presence of impurities in the product," he said.

    The particular problem they identified was with artemisinin-based drugs.
    The chemical is one of the few affordable and effective treatments for malaria.
    But the WHO's malaria programme chief Robert Newman said low-quality versions of the drug could increase resistance because they would not kill all of the parasites.

    "There are a number of things that need to be done - as a global community we need to support countries in strengthening their regulatory controls," Mr Newman said.

    The researchers also studied drugs from seven other countries - Cameroon, Ethiopia, Ghana, Kenya, Malawi, Nigeria and Tanzania - but have not yet released data from those nations.

    However, Mr Lukulay said Ghana had already withdrawn more than 20 drugs from the market after seeing initial results.
     
Loading...